The company made the announcement after market hours on Wednesday, 13 January 2010.

Meanwhile, the BSE Sensex was up 85.90 points, or 0.46%, to 17,590.36.

On BSE, 55,780 shares were traded in the counter as against an average daily volume of 72,893 shares in the past one quarter.

The stock hit a high of Rs 193 and a low of Rs 184.90 so far during the day. The stock hit a 52-week high of Rs 201.45 on 6 November 2009 and a 52-week low of Rs 67.50 on 13 March 2009.

The mid-cap stock had outperformed the market over the past one month till 13 January 2010, rising 3.55% as compared to the Sensex's 2.28% rise. It had underperformed the market in the past one quarter, falling 1.88% as compared to the Sensex's return of 2.84%.

The company's equity capital is Rs 54.72 crore. Face value per share is Rs 5.

Levofloxacin is the generic version of Ortho Mcneil's Levaquin. The drug is used for treating anti-bacterial diseases. As per IMS, the total annual market for the drug in the US is about $1.6 billion

Last week, Wockhardt received tentative approval from the US Food & Drug Administration (US FDA) for marketing Memantine Hydrochloride in multiple strengths. Memantine Hydrochloride is the generic version of Forrest Laboratories' Namenda tablets. As per IMS Health data, the total annual market for the drug in the US is around $1.1 billion.

Last month, Wockhardt received final approval from the US FDA for Ranitidine Hydrochloride tablets in multiple strengths. Ranitidine Hydrochloride is the generic version of GlaxoSmithKline's Zantac tablet. The drug is used for treating gastric ulcer.

Wockhardt reported a net loss of Rs 59.09 crore in Q3 September 2009 compared with a net profit of Rs 13.43 crore in Q3 September 2008. Net sales fell 2% to Rs 383.30 crore in Q3 September 2009 over Q3 September 2008.

Wockhardt specializes in the production of pharmaceuticals in both generic and prescription forms. The company has developed brands in a variety of segments, including anti-infective, pain & inflammation, cough, psychiatry, medical nutrition, vaccines, active pharmaceutical ingredients and biotechnology.

Promoters have pledged 5.78 crore shares representing 52.82% of the equity capital of the company. The total promoters shareholding in the company is 73.64% (as on 30 September 2009).